Risperidone-Loaded Nasal Thermosensitive Polymeric Micelles Quality by Design-Based Formulation Study /
The current research aims to develop thermosensitive polymeric micelles loaded with risperidone for nasal administration, emphasizing the added benefits of their thermosensitive behavior under nasal conditions. An initial risk assessment facilitated the advanced development process, confirming that...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2024
|
| Sorozat: | PHARMACEUTICS
16 No. 6 |
| Tárgyszavak: | |
| doi: | 10.3390/pharmaceutics16060703 |
| mtmt: | 34881352 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/34438 |
| LEADER | 01849nab a2200241 i 4500 | ||
|---|---|---|---|
| 001 | publ34438 | ||
| 005 | 20240826125241.0 | ||
| 008 | 240826s2024 hu o 000 eng d | ||
| 022 | |a 1999-4923 | ||
| 024 | 7 | |a 10.3390/pharmaceutics16060703 |2 doi | |
| 024 | 7 | |a 34881352 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sipos Bence | |
| 245 | 1 | 0 | |a Risperidone-Loaded Nasal Thermosensitive Polymeric Micelles |h [elektronikus dokumentum] : |b Quality by Design-Based Formulation Study / |c Sipos Bence |
| 260 | |c 2024 | ||
| 300 | |a 17 | ||
| 490 | 0 | |a PHARMACEUTICS |v 16 No. 6 | |
| 520 | 3 | |a The current research aims to develop thermosensitive polymeric micelles loaded with risperidone for nasal administration, emphasizing the added benefits of their thermosensitive behavior under nasal conditions. An initial risk assessment facilitated the advanced development process, confirming that the key indicators of thermosensitivity were suitable for nasal application. The polymeric micelles exhibited an average size of 118.4 ± 3.1 nm at ambient temperature and a size of 20.47 ± 1.2 nm at 36.5 °C, in both cases in monodisperse distribution. Factors such as pH and viscosity did not significantly impact these parameters, demonstrating appropriate nasal applicability. The model formulations showed a rapid, burst-like drug release profile in vitro, accompanied by a quick and high permeation rate at nasal conditions. Overall, the Quality by Design-based risk assessment process led to the development of an advanced drug delivery system capable of administering risperidone through the nasal cavity. | |
| 650 | 4 | |a Általános orvostudomány | |
| 700 | 0 | 1 | |a Katona Gábor |e aut |
| 700 | 0 | 2 | |a Pannonhalminé Csóka Ildikó |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/34438/1/pharmaceutics-16-00703.pdf |z Dokumentum-elérés |